199 related articles for article (PubMed ID: 27531363)
21. Patient-perceived satisfaction after definitive treatment for men with high-risk prostate cancer: radical prostatectomy vs. intensity-modulated radiotherapy with androgen deprivation therapy.
Yamamoto S; Masuda H; Urakami S; Fujii Y; Sakamoto K; Kozuka T; Oguchi M; Fukui I; Yonese J
Urology; 2015 Feb; 85(2):407-13. PubMed ID: 25623703
[TBL] [Abstract][Full Text] [Related]
22. High-dose adjuvant radiotherapy after radical prostatectomy with or without androgen deprivation therapy.
Ost P; Cozzarini C; De Meerleer G; Fiorino C; De Potter B; Briganti A; Nagler EV; Montorsi F; Fonteyne V; Di Muzio N
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):960-5. PubMed ID: 22172901
[TBL] [Abstract][Full Text] [Related]
23. Toxicity analysis of postoperative image-guided intensity-modulated radiotherapy for prostate cancer.
Nath SK; Sandhu AP; Rose BS; Simpson DR; Nobiensky PD; Wang JZ; Millard F; Kane CJ; Parsons JK; Mundt AJ
Int J Radiat Oncol Biol Phys; 2010 Oct; 78(2):435-41. PubMed ID: 19939580
[TBL] [Abstract][Full Text] [Related]
24. Incremental changes verses a technological quantum leap: the additional value of intensity-modulated radiotherapy beyond image-guided radiotherapy for prostate irradiation.
Ratnayake G; Martin J; Plank A; Wong W
J Med Imaging Radiat Oncol; 2014 Aug; 58(4):503-10. PubMed ID: 25243269
[TBL] [Abstract][Full Text] [Related]
25. Acute toxicity after image-guided intensity modulated radiation therapy compared to 3D conformal radiation therapy in prostate cancer patients.
Wortel RC; Incrocci L; Pos FJ; Lebesque JV; Witte MG; van der Heide UA; van Herk M; Heemsbergen WD
Int J Radiat Oncol Biol Phys; 2015 Mar; 91(4):737-44. PubMed ID: 25752386
[TBL] [Abstract][Full Text] [Related]
26. Impact of changing rectal dose volume parameters over time on late rectal and urinary toxicity after high-dose intensity-modulated radiotherapy for prostate cancer: A 10-years single centre experience.
Fonteyne V; Sadeghi S; Ost P; Vanpachtenbeke F; Vuye P; Lumen N; De Meerleer G
Acta Oncol; 2015 Jun; 54(6):854-61. PubMed ID: 25387271
[TBL] [Abstract][Full Text] [Related]
27. Image-guided dose-escalated intensity-modulated radiation therapy for prostate cancer: treating to doses beyond 78 Gy.
Eade TN; Guo L; Forde E; Vaux K; Vass J; Hunt P; Kneebone A
BJU Int; 2012 Jun; 109(11):1655-60. PubMed ID: 22035373
[TBL] [Abstract][Full Text] [Related]
28. Implantation of electromagnetic transponders following radical prostatectomy for delivery of IMRT.
Canter D; Greenberg RE; Horwitz EM; Kutikov A; Li J; Long C; Buyyounouski M; Boorjian SA
Can J Urol; 2010 Oct; 17(5):5365-9. PubMed ID: 20974028
[TBL] [Abstract][Full Text] [Related]
29. Image Guided Hypofractionated Postprostatectomy Intensity Modulated Radiation Therapy for Prostate Cancer.
Lewis SL; Patel P; Song H; Freedland SJ; Bynum S; Oh D; Palta M; Yoo D; Oleson J; Salama JK
Int J Radiat Oncol Biol Phys; 2016 Mar; 94(3):605-11. PubMed ID: 26867889
[TBL] [Abstract][Full Text] [Related]
30. Treatment decision regret and related factors following radical prostatectomy.
Lin YH
Cancer Nurs; 2011; 34(5):417-22. PubMed ID: 21242766
[TBL] [Abstract][Full Text] [Related]
31. Image-guided intensity-modulated radiotherapy of prostate cancer: Analysis of interfractional errors and acute toxicity.
Rudat V; Nour A; Hammoud M; Alaradi A; Mohammed A
Strahlenther Onkol; 2016 Feb; 192(2):109-17. PubMed ID: 26545764
[TBL] [Abstract][Full Text] [Related]
32. A Phase III trial to investigate the timing of radiotherapy for prostate cancer with high-risk features: background and rationale of the Radiotherapy -- Adjuvant Versus Early Salvage (RAVES) trial.
Pearse M; Fraser-Browne C; Davis ID; Duchesne GM; Fisher R; Frydenberg M; Haworth A; Jose C; Joseph DJ; Lim TS; Matthews J; Millar J; Sidhom M; Spry NA; Tang CI; Turner S; Williams SG; Wiltshire K; Woo HH; Kneebone A
BJU Int; 2014 Mar; 113 Suppl 2():7-12. PubMed ID: 24894850
[TBL] [Abstract][Full Text] [Related]
33. Radical prostatectomy vs. intensity-modulated radiation therapy in the management of localized prostate adenocarcinoma.
Aizer AA; Yu JB; Colberg JW; McKeon AM; Decker RH; Peschel RE
Radiother Oncol; 2009 Nov; 93(2):185-91. PubMed ID: 19800702
[TBL] [Abstract][Full Text] [Related]
34. Salvage intensity modulated radiotherapy using endorectal balloon after radical prostatectomy: clinical outcomes.
Ishiyama H; Teh BS; Blanco AI; Paulino AC; Mai WY; Caillouet J; Xu B; Butler EB
Int J Urol; 2013 Dec; 20(12):1178-83. PubMed ID: 23573867
[TBL] [Abstract][Full Text] [Related]
35. Intensity-modulated salvage radiotherapy with simultaneous integrated boost for local recurrence of prostate carcinoma: a pilot study on the place of PET-choline for guiding target volume delineation.
Wahart A; Guy JB; Vallard A; Geissler B; Ben Mrad M; Falk AT; Prevot N; de Laroche G; Rancoule C; Chargari C; Magné N
Br J Radiol; 2016; 89(1058):20150579. PubMed ID: 26648528
[TBL] [Abstract][Full Text] [Related]
36. Decisional regret after robotic-assisted laparoscopic prostatectomy is higher in African American men.
Collingwood SA; McBride RB; Leapman M; Hobbs AR; Kwon YS; Stensland KD; Schwartz RM; Pollard ME; Samadi DB
Urol Oncol; 2014 May; 32(4):419-25. PubMed ID: 24411791
[TBL] [Abstract][Full Text] [Related]
37. Relationship between pelvic organ-at-risk dose and clinical target volume in postprostatectomy patients receiving intensity-modulated radiotherapy.
Stanic S; Mathai M; Cui J; Purdy JA; Valicenti RK
Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1897-902. PubMed ID: 21536391
[TBL] [Abstract][Full Text] [Related]
38. Identification of factors predicting response to adjuvant radiation therapy in patients with positive margins after radical prostatectomy.
Kamat AM; Babaian K; Cheung MR; Naya Y; Huang SH; Kuban D; Babaian RJ
J Urol; 2003 Nov; 170(5):1860-3. PubMed ID: 14532793
[TBL] [Abstract][Full Text] [Related]
39. Longitudinal comparison of quality of life after real-time tumor-tracking intensity-modulated radiation therapy and radical prostatectomy in patients with localized prostate cancer.
Shinohara N; Maruyama S; Shimizu S; Nishioka K; Abe T; C-Hatanaka K; Oba K; Nonomura K; Shirato H
J Radiat Res; 2013 Nov; 54(6):1095-101. PubMed ID: 23660274
[TBL] [Abstract][Full Text] [Related]
40. Phase I trial of weekly docetaxel, total androgen blockade, and image-guided intensity-modulated radiotherapy for localized high-risk prostate adenocarcinoma.
Marshall DT; Ramey S; Golshayan AR; Keane TE; Kraft AS; Chaudhary U
Clin Genitourin Cancer; 2014 Apr; 12(2):80-6. PubMed ID: 24378335
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
